ClinicalTrials.gg
Sign In
Status unknownNCT04367714COVCKDUpdated Dec 30, 2020

Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19

An observational study in COVID and Terminal Renal Insufficiency, sponsored by Region MidtJylland Denmark. Status unknown at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-30.

Sponsored by Region MidtJylland Denmark · Observational

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

Determination of IgM and IgG antibodies against SARS-CoV-2 in dialysis patients by continous monitoring in the period from March 2020 to december 2020

Read the detailed description

Blood samples are collected every 14 days

02

Conditions studied

  • COVID
  • Terminal Renal Insufficiency

Browse trials for

Keywords

  • COVID-19
  • CKD 5
03

In context

COVID-19

7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.

This study's planned enrollment of 300 is above the median of 268 across 3,208 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Region MidtJylland Denmark is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Dilaysis patients on 3 Danish center in Jutland

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dialysis

Exclusion criteria

Exclusion Criteria:

  • Not willing to give consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
9 Months
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. AAntibody response

    IgM and IgG against SARS-CoV-2

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Godstrup Hospital
    Herning, 7400, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Dec 2021, 20 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 20 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2020
First posted
Apr 29, 2020
StartActual
Mar 15, 2020
Primary completionEst.
Dec 1, 2021
CompletionEst.
Dec 1, 2021
Last update
Dec 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04367714
Lead sponsor
Region MidtJylland Denmark
Collaborators
Aarhus University Hospital, Central Jutland Regional Hospital, Aalborg University Hospital
Responsible party
Frank Mose (MD PhD, Region MidtJylland Denmark) — Principal investigator
First posted
Apr 29, 2020
Start date
Mar 15, 2020
Primary completion
Dec 1, 2021 (estimated)
Completion
Dec 1, 2021 (estimated)
Last update
Dec 30, 2020

Study contacts

Frank Mose, MD
Contact
frchri@rm.dk
+4528531257

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

COVID-19 →

Other studies from this sponsor

Region MidtJylland Denmark

Start the discussion